The impact of the CYP2D6 "enhancer" single nucleotide polymorphism on CYP2D6 activity.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2469
Abstract: rs5758550 has been associated with enhanced transcription and suggested to be a useful marker of CYP2D6 activity. As there are limited and inconsistent data regarding the utility of this distant "enhancer" single nucleotide polymorphism (SNP),… read more here.
Keywords: cyp2d6; enhancer snp; cyp2d6 activity; impact cyp2d6 ... See more keywords
Advancing CYP2D6 Pharmacogenetics Through a Pharmacoequity Lens.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2890
Abstract: Over 20% of Food and Drug Administration (FDA)-approved drugs in the United States are metabolized by the hepatic enzyme cytochrome P450 2D6 (CYP2D6). The gene encoding CYP2D6 is highly polymorphic and genetic variation has been… read more here.
Keywords: genetic variation; cyp2d6 genetic; cyp2d6; variation ... See more keywords
Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.70012
Abstract: CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health inequity may be contributing to imprecise dose predictions for CYP2D6‐metabolizing… read more here.
Keywords: cyp2d6; risperidone metabolism; medicine; health ... See more keywords
Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo
Sign Up to like & getrecommendations! Published in 2024 at "European Journal of Clinical Pharmacology"
DOI: 10.1007/s00228-024-03721-6
Abstract: The CYP2D6 gene exhibits significant polymorphism, contributing to variability in responses to drugs metabolized by CYP2D6. While CYP2D6*2 and CYP2D6*35 are presently designated as alleles encoding normal metabolism, this classification is based on moderate level… read more here.
Keywords: cyp2d6 cyp2d6; cyp2d6; clearance; risperidone clearance ... See more keywords
Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-020-03206-w
Abstract: Purpose To review recent pharmacogenomics studies on breast cancer patients undergoing tamoxifen therapy, highlighting how our knowledge on cytochrome P450 2D6 (CYP2D6) can help to guide the development of adjuvant therapies for these patients. Methods… read more here.
Keywords: cyp2d6; tamoxifen; tamoxifen metabolism; breast cancer ... See more keywords
Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes
Sign Up to like & getrecommendations! Published in 2018 at "Archives of Pharmacal Research"
DOI: 10.1007/s12272-018-1030-6
Abstract: Tamsulosin, a selective antagonist of the α1-adrenoceptor, is primarily metabolized by CYP3A4 and CYP2D6, and tamsulosin exposure is significantly increased according to the genetic polymorphism of CYP2D6. In this study, we investigated the effects of… read more here.
Keywords: different cyp2d6; tamsulosin; cyp2d6 genotypes; cyp3a4 ... See more keywords
Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-019-00842-0
Abstract: A CYP2D6 gene polymorphism is related to the effect of tamoxifen treatment in patient with estrogen-receptor positive (ER) positive breast cancer and CYP2D6*10 T/T can lead to a poor prognosis in Asian patients. Although one-off… read more here.
Keywords: adjuvant endocrine; endocrine therapy; breast cancer; pharmacogenetic testing ... See more keywords
In vitro to in vivo extrapolation of the complex drug‐drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation
Sign Up to like & getrecommendations! Published in 2017 at "Biochemical Pharmacology"
DOI: 10.1016/j.bcp.2016.11.007
Abstract: Graphical abstract Figure. No Caption available. Abstract Bupropion is a widely used antidepressant and smoking cessation aid and a strong inhibitor of CYP2D6 in vivo. Bupropion is administered as a racemic mixture of R‐ and… read more here.
Keywords: cyp2d6; drug; bupropion metabolites; reversible inhibition ... See more keywords
Kinetic mechanism of time‐dependent inhibition of CYP2D6 by 3,4‐methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation
Sign Up to like & getrecommendations! Published in 2018 at "Biochemical Pharmacology"
DOI: 10.1016/j.bcp.2018.08.010
Abstract: Graphical abstract Figure. No Caption available. Abstract We investigate the mechanism of time‐dependent inhibition (TDI) of human cytochrome P450 2D6 (CYP2D6) by 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy), one of the most widespread recreational drugs of abuse. In… read more here.
Keywords: dependent inhibition; cyp2d6; time dependent; mechanism ... See more keywords
Results of the CYP-GUIDES randomized controlled trial: Total cohort and primary endpoints.
Sign Up to like & getrecommendations! Published in 2019 at "Contemporary clinical trials"
DOI: 10.1016/j.cct.2019.105910
Abstract: CYP-GUIDES (Cytochrome Psychotropic Genotyping Under Investigation for Decision Support) is a randomized controlled trial (RCT) comparing 2 outcomes in hospitalized patients with major depressive disorder (MDD) treated according to the patient's CYP2D6 genotype and functional… read more here.
Keywords: randomized controlled; trial; group; controlled trial ... See more keywords
Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation.
Sign Up to like & getrecommendations! Published in 2018 at "Drug metabolism and pharmacokinetics"
DOI: 10.1016/j.dmpk.2018.08.004
Abstract: Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolic activation of primaquine, an antimalarial drug. CYP2D6 is genetically polymorphic, and these polymorphisms are associated with interindividual variations observed in the therapeutic efficacy of primaquine. To… read more here.
Keywords: cyp2d6 allelic; cyp2d6; allelic variants; primaquine hydroxylation ... See more keywords